VALN News and Press, Valneva SE From 04/14/22

Gainers: Lexaria Bioscience (LEXX) +23%. Rite Aid (RAD) +14%. Inozyme Pharma (INZY) +12%. Finch Therapeutics (FNCH) +11%. Valneva (VALN) +9%. Losers: Protagonist Therapeutics (PTGX) -23%. Lixte Biotechnology (LIXT) -10%. Biofrontera (BFRI) ...

The U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) approved Valneva's (NASDAQ:VALN) (OTCPK:INRLF) COVID-19 vaccine. The conditional marketing authorization (CMA) granted by the MHRA is valid in Britain and Northern Ireland. MHRA said it is the first in the world to app...

Should Investors Be Watching These Top Health Care Stocks This Week? In the past 2 years, health care stocks have been among the more important sectors in the stock market thanks to the Covid-19 pandemic. Although new daily cases in the country have been relatively low compared ...

The following slide deck was published by Valneva SE in conjunction with their 2021 Q4 earnings call. For further details see: Valneva SE 2021 Q4 - Results - Earnings Call Presentation

Valneva SE (VALN) Q4 2021 Earnings Conference Call March 24, 2022, 10:00 AM ET Company Participants Thomas Lingelbach - Chairman, President and CEO Peter Buhler - CFO Conference Call Participants Maury Raycroft - Jeffries Seamus Fernandez - Guggenheim Securities Samir Devani - Rx Securities L...

4 Health Care Stocks For Your Mid-March Watchlist With the stock market continuing to tread water, many investors are looking for safer investments to fend off the volatility. While we may not be in a bear market as far as the main indices are concerned, it’s never a bad ...

Valneva (NASDAQ:VALN) (OTCPK:INRLF) expects to receive a positive recommendation from the European Medicines Agency (EMA) in April for the conditional approval of its COVID-19 vaccine VLA2001. The company said it has received a small set of additional questions from the EMA's C...

Today, we 'circle back' on Dynavax Technologies, a biotech concern that just delivered solid fourth quarter results. The company is set up for a good 2022 as both its Covid vaccine adjuvant and hepatitis B vaccine sales continue to show impressive growth. A full investment analysi...

Valneva (OTCPK:INRLF) said the National Health Regulatory Authority (NHRA) of the Kingdom of Bahrain has granted emergency use authorization for its COVID-19 vaccine VLA2001. The authorization follows a rolling review process with the Bahraini NHRA. "We are extremely pleased with this first a...

Valneva (NASDAQ:VALN) received a list of questions from a committee of the European Medicines Agency (EMA) regarding its COVID-19 vaccine candidate, VLA2001. The company said that it is confident that it will be able to respond to the questions by the EMA's Committee for Medicinal P...